Moomoo AI 已提取核心信息
TransCode Therapeutics, Inc., a biotech company listed under the ticker RNAZ.US, has moved to accelerate the effective date of its registration statement on Form S-1, as per a correspondence with the U.S. Securities and Exchange Commission (SEC) dated January 17, 2024. The placement agent, H.C. Wainwright & Co., LLC, has concurred with TransCode's request to advance the effective date to 5:15 P.M. Eastern Time on the same day, or as soon as practicable thereafter. This acceleration is in accordance with Rule 461 under the Securities Act. H.C. Wainwright & Co., acting solely as a placement agent on a best-efforts basis for the offering, acknowledges its obligations under the Securities Act in relation to the offering.
TransCode Therapeutics, Inc., a biotech company listed under the ticker RNAZ.US, has moved to accelerate the effective date of its registration statement on Form S-1, as per a correspondence with the U.S. Securities and Exchange Commission (SEC) dated January 17, 2024. The placement agent, H.C. Wainwright & Co., LLC, has concurred with TransCode's request to advance the effective date to 5:15 P.M. Eastern Time on the same day, or as soon as practicable thereafter. This acceleration is in accordance with Rule 461 under the Securities Act. H.C. Wainwright & Co., acting solely as a placement agent on a best-efforts basis for the offering, acknowledges its obligations under the Securities Act in relation to the offering.
根据2024年1月17日与美国证券交易委员会（SEC）的通信，股票代码为RNAZ.US的生物技术公司TransCode Therapeutics, Inc. 已采取行动加快其S-1表格注册声明的生效日期。配售代理机构H.C. Wainwright & Co., LLC已同意TransCode的请求，将生效日期提前至美国东部时间当天下午5点15分，或在此后尽快生效。这种加速符合《证券法》第461条。H.C. Wainwright & Co. 在最大努力的基础上仅作为配售代理行事，承认其根据《证券法》承担的与本次发行相关的义务。
根据2024年1月17日与美国证券交易委员会（SEC）的通信，股票代码为RNAZ.US的生物技术公司TransCode Therapeutics, Inc. 已采取行动加快其S-1表格注册声明的生效日期。配售代理机构H.C. Wainwright & Co., LLC已同意TransCode的请求，将生效日期提前至美国东部时间当天下午5点15分，或在此后尽快生效。这种加速符合《证券法》第461条。H.C. Wainwright & Co. 在最大努力的基础上仅作为配售代理行事，承认其根据《证券法》承担的与本次发行相关的义务。
有用
没用
该公告为独立文件：
